Please read this leaflet if you have been prescribed Cosentyx® (secukinumab) 300 mg

This is a different pen from the **150 mg** dose and so will affect the administration of your medication



Always use Cosentyx® exactly as your doctor or nurse has described.

This leaflet does not replace the Patient Information Leaflet (PIL) that is provided with your medication, or advice from your doctor or nurse. Always read the PIL before starting your treatment and use Cosentyx® exactly as your doctor or nurse has described.

It is important not to try to inject yourself until you have been trained by your doctor, nurse, or pharmacist – check with them if you are unsure.

 $\textbf{This leaflet is intended for adult patients who have been prescribed Cosenty} \textbf{x}^{\texttt{@}}. \textbf{For distribution by healthcare professionals only}.$

It has been produced and funded by Novartis Pharmaceuticals UK Ltd. UK \mid May 2023 \mid 273590

© 2023 Novartis Pharmaceuticals UK Ltd





How does this impact your dosing schedule?

Please reach out to your doctor or healthcare team if you have any questions

Make sure you check the pen that you receive and only administer ONE UnoReady® pen injection as prescribed by your doctor, as you may have an alternative dosing schedule

Your doctor will decide how much Cosentyx® you need and for how long.¹

Recommended dosing

After the first dose you will receive further weekly injections at Weeks 1, 2, 3, and 4 followed by monthly maintenance injections. Based on your response, further adjustments to your dose may be recommended by your doctor.¹

Adult plaque psoriasis

The recommended dose is 300 mg by subcutaneous injection.¹

Adult psoriatic arthritis

If you have both psoriatic arthritis and moderate to severe plaque psoriasis, your doctor may adjust your dose as needed.1

For patients who did not respond well to medicines called tumour necrosis factor (TNF) blockers, the recommended dose is 300 mg by subcutaneous injection.¹


For other patients with psoriatic arthritis, the recommended dose is 150 mg by subcutaneous injection.¹

Ankylosing spondylitis (radiographic axial spondyloarthritis):

The recommended dose is 150 mg by subcutaneous injection. Based on your response, your doctor may increase your dose to 300 mg.1

Non-radiographic axial spondyloarthritis:


The recommended dose is 150 mg by subcutaneous injection.¹



The UnoReady® 300 mg pen provides a 300 mg dose in one injection¹

Please reach out to your doctor or healthcare team if you have any questions

The pen allows you to take your 300 mg dose in ONE injection instead of TWO



...and has some similar features to the SensoReady® 150 mg pen^{1,2}



Similar administration to the SensoReady® 150 mg pen^{1,2}

Please reach out to your doctor or healthcare team if you have any questions

Please read the instruction leaflet that can be found inside the Cosentyx® pack before using your UnoReady® pen

PREPARE

- Take your UnoReady® 300 mg pen out of the refrigerator **30–45 minutes** before you want to use it and allow it to come to **room temperature.** This is longer than you might be used to with the SensoReady® pen
- · Prepare your skin for injection using an alcohol wipe
- Only take the cap off when you are ready to use the pen to inject the dose
- When injecting using the UnoReady® pen, remember to Click, Watch, Click & Wait
- Make sure you hold down the UnoReady® pen firmly at the injection site, to ensure the injection can be completed

CLICK

Press the pen firmly against your skin, at 90 degrees to the body, to start the injection. The **1st click** indicates that the injection has started.

WATCH

Keep holding the pen firmly against your skin. A green indicator with a grey tip will start to fill the device window as the injection continues. The UnoReady® pen may take slightly longer to administer than the SensoReady® pen.

CLICK & WAIT

Several seconds later, a **2nd click** will tell you that the injection is almost finished. When the green indicator with a grey tip fills the window and stops moving, the injection is complete. **Top tip:** Wait for a couple of seconds after the second click if you cannot see the window.

References

- $1. \ Cosentyx @ 300 \ mg \ Patient Information Leaflet. \ Available \ at: \ https://www.medicines.org.uk/emc/files/pil.11973.pdf (Accessed April 2023).$
- 2. Cosentyx @ 150 mg Patient Information Leaflet. Available at: https://www.medicines.org.uk/emc/files/pil.3669.pdf (Accessed April 2023). A consensus of the contraction of the contr

Safety information

Stop using Cosentyx® and tell your doctor or seek medical help immediately if you experience any of the following side effects:

- Serious side effects: possible serious infection (signs may include: fever, flu-like symptoms, feeling tired or short of breath, persistent cough, red and/or painful skin that may be blistered, or a burning sensation when urinating) or serious allergic reaction (signs may include: difficulty breathing/swallowing, low blood pressure which may cause dizziness or a light-headed feeling, swelling of the face/lips/tongue/throat, severe itching of the skin with a red rash/bumps)
- Very common side effects: upper respiratory tract infections (signs may include a sore throat or stuffy nose)
- Common side effects: cold sores, diarrhoea, runny nose, athlete's foot, headache, nausea, fatigue

Reporting side effects:

If you get side effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the information leaflet that comes in the pack. You can also report side effects via the Yellow Card Scheme at <u>yellowcard.mhra.gov.uk</u> (UK). By reporting side effects you can help provide more information on the safety of your medication.



